Aspira Women's Health (AWH) Q2 2026 earnings summary

Executive summary

• Revenue for the quarter ended June 30, 2026, decreased 15% year-over-year to $2.0 million, driven by a 12% decline in OvaSuite test volume due to reduced field sales headcount.

• Net loss for the quarter was $2.4 million, an improvement from a $2.7 million loss in the prior year period, reflecting lower operating expenses.

• Gross profit margin declined to 55.3% from 63.8% year-over-year, primarily due to lower revenue and increased cost of revenue.

• The company continues to focus on expanding its product pipeline, including ENDOinform and OVAinform, and entered a new collaboration with Cleveland Clinic Foundation in May 2026.

Financial highlights

• Revenue for the six months ended June 30, 2026, was $4.0 million, down 14% year-over-year.

• Gross profit for the six months was $2.2 million, with a gross margin of 54.9%, down from 66.1% in the prior year.

• Operating expenses for the six months decreased 23% to $6.2 million, driven by reductions in sales, marketing, and general administrative costs.

• Net loss for the six months was $1.7 million, a significant improvement from a $4.5 million loss in the prior year.

• Cash and cash equivalents as of June 30, 2026, were $477,000, with a working capital deficit of $2.5 million.

Outlook and guidance

• Management expects revenue to increase in the third quarter of 2026 due to a focus on higher revenue-generating payers.

• The company anticipates continued net losses and negative cash flows from operations for the remainder of 2026.

• There is substantial doubt about the company's ability to continue as a going concern within one year without additional financing or a significant increase in revenue.